Mario Boccadoro

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. ncbi request reprint The future role of thalidomide in multiple myeloma
    Mario Boccadoro
    Divisione di Ematologia, Ospedale Molinette, Torino, Italy
    Acta Haematol 114:18-22. 2005
  2. pmc Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    Mario Boccadoro
    Section of Hematology, University of Torino, Torino, Italy
    Cancer Cell Int 5:18. 2005
  3. ncbi request reprint Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma
    Mario Boccadoro
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Haematologica 87:846-50. 2002
  4. ncbi request reprint Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
    Marco Ladetto
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Torino, Italy
    Biol Blood Marrow Transplant 12:1270-6. 2006
  5. doi request reprint Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:800-7. 2010
  6. doi request reprint Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
    Marco Ladetto
    Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:2077-84. 2010
  7. doi request reprint Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
    Francesca Gay
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
    Blood 122:1376-83. 2013
  8. ncbi request reprint Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Italy
    Clin Lymphoma Myeloma 6:475-7. 2006
  9. ncbi request reprint Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy
    Antonio Palumbo
    Division of Hematology, University of Torino, San Giovanni Battista Hospital, Turin, Italy
    Cancer 110:824-9. 2007
  10. ncbi request reprint Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Eur J Haematol 75:391-5. 2005

Detail Information

Publications109 found, 100 shown here

  1. ncbi request reprint The future role of thalidomide in multiple myeloma
    Mario Boccadoro
    Divisione di Ematologia, Ospedale Molinette, Torino, Italy
    Acta Haematol 114:18-22. 2005
    ..The workshop acknowledged the problems associated with designing a phase III study, and it is clear that many areas need to be addressed in the use of thalidomide for the treatment of multiple myeloma...
  2. pmc Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    Mario Boccadoro
    Section of Hematology, University of Torino, Torino, Italy
    Cancer Cell Int 5:18. 2005
    ....
  3. ncbi request reprint Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma
    Mario Boccadoro
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Haematologica 87:846-50. 2002
    ....
  4. ncbi request reprint Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
    Marco Ladetto
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Torino, Italy
    Biol Blood Marrow Transplant 12:1270-6. 2006
    ..Our results indicate that rituximab is active against residual MCL cells and suggest that molecularly tailored maintenance therapy needs to be investigated in clinical trials...
  5. doi request reprint Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:800-7. 2010
    ..CONCLUSION Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance, is an effective regimen...
  6. doi request reprint Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
    Marco Ladetto
    Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:2077-84. 2010
    ..Moreover, the major reduction in tumor load recorded by RQ-PCR after VTD suggests that unprecedented levels of tumor cell reduction can be achieved in MM thanks to the new nonchemotherapeutic drugs...
  7. doi request reprint Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
    Francesca Gay
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
    Blood 122:1376-83. 2013
    ..024). Bortezomib-induction followed by ASCT and lenalidomide consolidation-maintenance is a valuable option for elderly myeloma patients, with the greatest benefit in those younger than 70 years of age. ..
  8. ncbi request reprint Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Italy
    Clin Lymphoma Myeloma 6:475-7. 2006
    ..Bortezomib and thalidomide have shown synergy with melphalan and dexamethasone. We used this 4-drug combination as conditioning before autologous hematopoietic cell infusions...
  9. ncbi request reprint Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy
    Antonio Palumbo
    Division of Hematology, University of Torino, San Giovanni Battista Hospital, Turin, Italy
    Cancer 110:824-9. 2007
    ..Baseline parameters that may be predictive of outcome after thalidomide treatment have been investigated to identify which myeloma patient subgroups will most benefit from this drug...
  10. ncbi request reprint Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Eur J Haematol 75:391-5. 2005
    ..The aim of the study was to define the best treatment option for patients relapsing after AT...
  11. ncbi request reprint Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia, l Università di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Turin, Italy
    Eur J Haematol 76:273-7. 2006
    ..To address this issue, feasibility and efficacy of a three drug combination consisting of intravenous (i.v.) melphalan, thalidomide and prednisone [M(i.v.)PT] was evaluated in advanced myeloma patients...
  12. doi request reprint Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey
    Corrado Tarella
    Dipartimento Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Az Osp S Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 26:3166-75. 2008
    ..To investigate the impact of adding rituximab to intensive chemotherapy with peripheral-blood progenitor cell (PBPC) autograft for high-risk diffuse large B-cell lymphoma (DLB-CL) and follicular lymphoma (FL)...
  13. doi request reprint Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
    Fortunato Morabito
    UOC Ematologia, A O di Cosenza, Torino, Italy
    Am J Hematol 89:355-62. 2014
    ..Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT...
  14. doi request reprint Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
    ....
  15. doi request reprint Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 112:3107-14. 2008
    ..34). These data confirm activity of MPT for PFS but failed to show any survival advantage. New agents in the management of relapsed disease could explain this finding. The study is registered at www.clinicaltrials.gov as #NCT00232934...
  16. pmc Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
    Luisa Giaccone
    Division of Hematology, San Giovanni Battista Hospital, University of Torino, Via Genova 3, Turin, Italy
    Blood 117:6721-7. 2011
    ..7 (P = .01) years, respectively. Allografting conferred a long-term survival and disease-free advantage over standard autografting in this comparative study...
  17. ncbi request reprint Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera AO S Giovanni Battista, Turin, Italy
    Blood 109:2767-72. 2007
    ..Initial results showed that VMPT is an effective salvage therapy with a very high proportion of responses. The incidence of neurotoxicities was unexpectedly low...
  18. doi request reprint Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria S Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    Blood 115:1873-9. 2010
    ..We conclude that MEL200 leads to longer remission duration and should be considered the standard conditioning regimen for autologous transplantation. This study was registered at www.clinicaltrials.gov as #NCT00950768...
  19. doi request reprint Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
    Alessandra Larocca
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Blood 122:2799-806. 2013
    ..New grade 3 to 4 adverse events were low during maintenance. Pomalidomide-cyclophosphamide-prednisone is safe and effective in relapsed/refractory myeloma patients. This trial was registered at www.clinicaltrials.gov as #NCT01166113. ..
  20. ncbi request reprint Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, 10126 Torino, Italy
    Lancet 367:825-31. 2006
    ..This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years...
  21. doi request reprint Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
    Alessandra Larocca
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria AOU S Giovanni Battista, Torino, Italy
    Blood 119:933-9; quiz 1093. 2012
    ..No major hemorrhagic complications were reported. In previously untreated patients with MM receiving lenalidomide with a low thromboembolic risk, ASA could be an effective and less-expensive alternative to LMWH thromboprophylaxis...
  22. pmc Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
    Antonio Palumbo
    Divisione, di Ematologia Dell Università di Torino, Azienda Ospedaliera San, Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    Haematologica 95:1144-9. 2010
    ....
  23. doi request reprint Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry
    Roberto Passera
    Divison of Nuclear Medicine 2, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Biol Blood Marrow Transplant 19:940-8. 2013
    ..Long-term disease control remains challenging regardless of the conditioning. In the light of these results, prospective trials may be designed to better define the role of allografting from unrelated donors in myeloma...
  24. ncbi request reprint Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Turin, Italy
    Cancer 104:1428-33. 2005
    ..No data are available on the association of thalidomide with oral melphalan and prednisone, still considered the standard treatment for elderly patients...
  25. doi request reprint Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
    Sara Bringhen
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria S Giovanni Battista, Torino, Italy
    Blood 116:4745-53. 2010
    ..001). This improvement in safety did not appear to affect efficacy. This study is registered at http://www.clinicaltrials.gov as NCT01063179...
  26. doi request reprint Treatment of newly diagnosed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Via Genova 3, Turin, Italy
    Curr Hematol Malig Rep 3:107-14. 2008
    ..The introduction of thalidomide, bortezomib, and lenalidomide, which target MM cells and the bone marrow microenvironment, has changed the therapeutic options in newly diagnosed patients with MM...
  27. doi request reprint Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Clin Lymphoma Myeloma 9:145-50. 2009
    ..This updated analysis reassessed the kinetics of neutropenia and thrombocytopenia as well as the safety and efficacy of MPR...
  28. pmc Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
    Sara Bringhen
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Haematologica 98:980-7. 2013
    ..A detailed geriatric assessment, organ evaluation and less intense individualized approaches are suggested in elderly unfit subjects...
  29. ncbi request reprint Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy
    Hematol J 5:318-24. 2004
    ..The clinical outcome of patients treated with THAL-DEX was compared with that of a control group treated with conventional chemotherapy (CC)...
  30. ncbi request reprint Investigational treatments for multiple myeloma
    Sara Bringhen
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    Expert Opin Investig Drugs 15:1565-82. 2006
    ..Their mechanisms of action, the available knowledge on their efficacy, safety and possible future clinical application are reviewed...
  31. ncbi request reprint Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma
    Benedetto Bruno
    Division of Hematology at the San Giovanni Battista Hospital, University of Torino, Torino, Italy
    Eur J Haematol 78:330-7. 2007
    ..We investigated the feasibility of unrelated donor non-myeloablative transplantation as either part of the initial treatment plan or as salvage treatment in heavily pretreated patients...
  32. doi request reprint Update on recent developments for patients with newly diagnosed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Ann N Y Acad Sci 1138:19-21. 2008
    ..Combination regimens containing bortezomib or thalidomide can achieve response rates, especially complete response rates, which are superior to those seen with standard MP alone, and offer new possibilities for this patient population...
  33. ncbi request reprint Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    J Clin Oncol 25:4459-65. 2007
    ..We assessed dosing, efficacy, and safety of melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed elderly myeloma patients...
  34. doi request reprint Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
    Antonio Palumbo
    University of Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Torino, Italy
    J Clin Oncol 29:986-93. 2011
    ....
  35. pmc Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
    Benedetto Bruno
    Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy
    Blood 113:3375-82. 2009
    ..http://ClinicalTrials.gov; NCT-00702247.)...
  36. doi request reprint Lenalidomide and its role in the management of multiple myeloma
    Patrizia Falco
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Expert Rev Anticancer Ther 8:865-74. 2008
    ..Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma...
  37. doi request reprint Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
    Francesca Gay
    Myeloma Unit, Division of Hematology, University of Torino, AOU S Giovanni Battista, Torino, Italy
    Blood 117:3025-31. 2011
    ..This trial was registered at www.clinicaltrials.gov as #NCT00232934, #ISRCTN 90692740, and #NCT01063179...
  38. ncbi request reprint A new standard of care for elderly patients with myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino 10126, Italy
    Lancet 370:1191-2. 2007
  39. doi request reprint Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surviva
    Marco Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
    Blood 111:4004-13. 2008
    ..This trial was registered at www.clinicaltrials.gov as no. NCT00435955...
  40. doi request reprint Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells
    Marta Coscia
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Italy
    Blood 120:3271-9. 2012
    ..These results unveil a clinically relevant in vivo relationship between the mevalonate pathway activity of CLL cells and dys-functional Vγ9Vδ2 T cells...
  41. doi request reprint Current treatment strategies with lenalidomide in multiple myeloma and future perspectives
    Alessandra Larocca
    Myeloma Unit, Division of Hematology, University of Torino, AOU S Giovanni Battista, Torino, Italy
    Future Oncol 8:1223-38. 2012
    ....
  42. ncbi request reprint Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
    Marco Ladetto
    Dipartimento di Medicina ed Oncologia Sperimentale, Servizio di Epidemiologia dei Tumori e Biostatistica, Centro di Ricerca in Medicina Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Blood 105:4784-91. 2005
    ..Future studies will assess COX-2 involvement in other hematologic tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology...
  43. ncbi request reprint Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
    Marco Ladetto
    Divisione di Ematologia Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, A O San Giovanni Battista della Citta di Torino, Torino, Italy
    Exp Hematol 31:784-8. 2003
    ....
  44. doi request reprint Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma
    Simone Ferrero
    Division of Hematology, AOU San Giovanni Battista, University of Torino, Via Genova 3, 10126, Torino, Italy
    Ann Hematol 92:1503-11. 2013
    ..pRTX was feasible and safe and effectively reinduced MR in FL and MCL patients (74 %). Prospective trials are needed to verify the clinical benefit of similar approaches...
  45. ncbi request reprint Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid
    Francesca Fiore
    Division of Hematology, University of Turin, Via Genova 3, 10126 Turin, Italy
    Blood 110:921-7. 2007
    ..This strategy is worthy of further investigation to improve adoptive cell therapy and vaccine interventions against tumors and infections...
  46. ncbi request reprint Melphalan and its role in the management of patients with multiple myeloma
    Patrizia Falco
    Azienda Ospedaliera San Giovanni Battista, Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Expert Rev Anticancer Ther 7:945-57. 2007
    ....
  47. ncbi request reprint Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations
    Marco Ladetto
    Divisione di Ematologia Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino A O San Giovanni Battista della Citta di Torino, Torino, Italy
    Exp Hematol 34:1680-6. 2006
    ..To address these issues we prospectively monitored a panel of NLABR-positive LFS...
  48. doi request reprint Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
    Stefania Oliva
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospeadliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
    Oncotarget . 2016
    ..MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments...
  49. doi request reprint How to manage neutropenia in multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Turin, Italy
    Clin Lymphoma Myeloma Leuk 12:5-11. 2012
    ..If ANC restores to > 1000 cells/mL, therapy can be resumed with no dose modifications. In case of persistence of severe neutropenia, treatment should be delayed until ANC reaches > 1000 cells/mL, and dose reductions are necessary...
  50. pmc Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
    Enrico Maffini
    Department of Oncology, SSCVD Trapianto di Cellule Staminali, A O U Città della Salute e della Scienza di Torino, Torino, Italy
    J Hematol Oncol 9:67. 2016
    ..Ruxolitinib, a JAK1/2 inhibitor approved for intermediate-2/high-risk myelofibrosis, was recently employed in SR-GvHD with encouraging overall response rates. Clinical experience however remains limited...
  51. doi request reprint Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma
    Sara Bringhen
    University of Torino, AOU S Giovanni Battista, Division of Hematology, Myeloma Unit, Torino, Italy
    Expert Opin Drug Metab Toxicol 8:1209-22. 2012
    ..It has been used for the treatment of newly diagnosed and relapsed MM patients, as both maintenance and preventive therapy. Available data show a progression-free survival and overall survival improvement associated with this drug...
  52. doi request reprint Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation
    Luisa Giaccone
    Division of Hematology, SGB Hospital, University of Torino, Torino, Italy
    Biol Blood Marrow Transplant 16:809-17. 2010
    ....
  53. doi request reprint Role of allogeneic stem cell transplantation in multiple myeloma
    Benedetto Bruno
    Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy
    Semin Hematol 46:158-65. 2009
    ..An overview of the clinical outcomes obtained with allografting and possible future developments are reported...
  54. pmc Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma
    Chiara Lobetti-Bodoni
    Hematology Division I, Azienda Ospedaliera San Giovanni Battista, Città della Salute e della Scienza, Torino, Italy
    Ther Adv Hematol 4:189-98. 2013
    ..Then, the bulk of the review focuses on critical take-home messages for clinicians working in the field. Finally, we discuss future perspectives of MRD detection and more generally outcome prediction in FL...
  55. pmc European perspective on multiple myeloma treatment strategies in 2014
    Heinz Ludwig
    Department of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom Department of Hematology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain Divisione di Ematologia dell Università di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Turin, Italy Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy Haemato Oncology Unit, Royal Marsden Hospital, Surrey, United Kingdom Hematology Service, University Hospital La Fe, Valencia, Spain Department of Hematology, University Hospital, Leuven, Belgium Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Wurzburg, Germany Service d Hématologie, Centre Hospitalier Universitaire, Lille, France Department of Internal Medicine V, University of Heidelberg, Heidelberg, McLean Hospital/Harvard Medical School
    Oncologist 19:829-44. 2014
    ..A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results. ..
  56. doi request reprint Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
    Valeria Magarotto
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria AOU Città della Salute e della Scienza di Torino, Torino, Italy
    Blood 127:1102-8. 2016
    ..This study was registered at www.clinicaltrials.gov as #NCT01093196. ..
  57. doi request reprint Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
    Sara Bringhen
    Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
    Blood 124:63-9. 2014
    ..In summary, results showed high complete response rates and a good safety profile. This trial was registered at clinicaltrials.gov as #NCT01346787. ..
  58. ncbi request reprint Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir
    Alberto Rocci
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale Universita di Torino, Italy
    Exp Hematol 35:673-81. 2007
    ..To investigate telomere length (TL) and hematopoietic progenitors in long-term survivors after high-dose chemotherapy and peripheral blood stem cell (PBSC) autograft...
  59. doi request reprint Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
    Antonio Palumbo
    Division of Hematology, University of Torino, Azinda Ospedaliero Universitaria S Giovanni Battista, Torino, Italy
    Blood 118:4519-29. 2011
    ..Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes...
  60. ncbi request reprint The treatment of the elderly multiple myeloma patients
    Federica Cavallo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Leuk Lymphoma 48:469-80. 2007
    ..In this review we present the data available on the most recent trials dealing with the treatment of elderly MM patients...
  61. ncbi request reprint Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders
    Marco Ladetto
    Cattedra di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Blood 103:4644-9. 2004
    ....
  62. pmc Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies
    Simona Caltagirone
    Divisione di Ematologia, Universita di Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Italy Scuola di specializzazione in medicina clinica, Universita di Torino, Italy
    Haematologica 99:1611-7. 2014
    ..This trial was registered at www.clinicaltri-als.gov as #NCT01063179. ..
  63. doi request reprint MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients
    Alberto Rocci
    Myeloma Unit, Division of Haematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Br J Haematol 164:841-50. 2014
    ..High MET mRNA expression identifies patients with dismal PFS and OS and the combination with high β2-microglobulin further characterizes patients with worse outcome...
  64. pmc Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Turin, AOU S Giovanni Battista, Torino, Italy
    Haematologica 98:87-94. 2013
    ..Serious non-hematologic toxicities, older age, poor Performance Status, and high creatinine levels negatively affected survival...
  65. doi request reprint The impact of response on bone-directed therapy in patients with multiple myeloma
    Alessandra Larocca
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Blood 122:2974-7. 2013
    ..0091). No difference in OS was seen with patients in CR (P = .91) or VGPR (P = .74). These findings indicate that response category posttransplant may influence the impact of bisphosphonate therapy...
  66. ncbi request reprint Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma
    Mara Compagno
    Divisione di Ematologia, Universita di Torino, Torno, Italy
    Methods Mol Med 113:145-63. 2005
    ..Although real-time PCR is the main focus of the chapter, most of the information suitable for a proper setup of a qualitative approach is also provided...
  67. ncbi request reprint Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
    Blood 104:3052-7. 2004
    ..Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients...
  68. ncbi request reprint Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3
    Alessandra Cuttica
    Dipartimento di Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Cancer 98:983-92. 2003
    ....
  69. doi request reprint Management of myeloma: an Italian perspective
    Benedetto Bruno
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, Italy
    Clin Lymphoma Myeloma Leuk 11:S82-6. 2011
    ..Whether these new advancements in myeloma treatment will eventually translate into a long chronic phase or a monoclonal gammopathy of undetermined significance-like status for the majority of patients remains, however, still unanswered...
  70. ncbi request reprint Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests
    Marco Ladetto
    Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Exp Hematol 30:529-36. 2002
    ..In this study, we used a validated real-time polymerase chain reaction (PCR) strategy to evaluate LTC of BM and PBPC samples obtained from MM patients...
  71. ncbi request reprint Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation
    Benedetto Bruno
    Division of Hematology, Azienda Ospedaliera San Giovanni Battista, University of Torino, Torino, Italy
    Haematologica 91:837-9. 2006
    ..After a median follow-up of 6 months, progression free survival was 6 months. Twenty-one patients are alive, two and five in continuous very good partial and complete remissions, respectively...
  72. doi request reprint Thalidomide for treatment of multiple myeloma: 10 years later
    Antonio Palumbo
    Division of Hematology, University of Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 111:3968-77. 2008
    ..Future studies will define the most effective or the best sequence of combinations which could improve life expectancy...
  73. ncbi request reprint High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients
    Corrado Tarella
    Dipartimento Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy
    Cancer 97:2748-59. 2003
    ....
  74. pmc Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
    Marta Coscia
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria S Giovanni Battista di Torino, Torino, Italy
    J Cell Mol Med 14:2803-15. 2010
    ....
  75. ncbi request reprint PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy
    Marco Ladetto
    Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale Universita di Torino, Italy
    J Clin Oncol 21:1398-403. 2003
    ....
  76. ncbi request reprint Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma
    Giorgia Maria Elena Matta
    Divisione di Ematologia dell Universita di Torino, Ospedale San Giovanni Battista, Torino, Italy
    Clin Cancer Res 13:5348-54. 2007
    ..We have determined IgE levels in a large series of MM patients at diagnosis and subjects with monoclonal gammopathy of undetermined significance (MGUS) and correlated IgE levels with survival and prognostic factors in MM...
  77. doi request reprint Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy
    Vincenzo Squadrone
    Dipartimento di Anestesia e di Medicina degli Stati Critici, Azienda Ospedaliera S Giovanni Battista Molinette, Universita di Torino, Corso Dogliotti 14, 10126 Turin, Italy
    Intensive Care Med 36:1666-74. 2010
    ..The aim of this study is to determine the effectiveness of early continuous positive airway pressure (CPAP) delivered in the ward to prevent occurrence of ALI requiring intensive care unit (ICU) admission for mechanical ventilation...
  78. ncbi request reprint Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation
    Benedetto Bruno
    Division of Haematology, Department of Medicine and Experimental Oncology, Centro di Ricerca in Medicina Sperimentale, University of Turin, Ospedale San Giovanni Battista, Italy
    Eur J Haematol 76:342-7. 2006
    ..Tumour lesions completely receded when immunosuppression was tapered. Prevalence studies in donors and recipients are needed to determine the clinical impact of HHV-8 in HCT...
  79. ncbi request reprint New drugs for treatment of multiple myeloma
    Benedetto Bruno
    Division of Haematology, University of Turin, Department of Medicine and Experimental Oncology, Laboratory of Haematology and Oncology, Centro di Ricerca in Medicina Sperimentale, Ospedale San Giovanni Battista, Italy
    Lancet Oncol 5:430-42. 2004
    ..Here, we discuss the mechanisms of action of these new rational drugs and the preliminary clinical outcomes of a new treatment regimen for MM...
  80. ncbi request reprint A comparison of allografting with autografting for newly diagnosed myeloma
    Benedetto Bruno
    San Giovanni Battista Hospital, University of Turin, Turin, Italy
    N Engl J Med 356:1110-20. 2007
    ..In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts...
  81. doi request reprint International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Torino 10126, Italy
    Leukemia 23:1716-30. 2009
    ..These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM...
  82. pmc Role of allogeneic transplantation in multiple myeloma in the era of new drugs
    Benedetto Bruno
    Division of Hematology at the S Giovanni Battista Hospital, University of Torino, Via Genova 3, Torino, Italy
    Mediterr J Hematol Infect Dis 2:e2010013. 2010
    ..However, this combination should be explored only in well-designed clinical trials...
  83. doi request reprint A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
    Elena Crisà
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista di Torino, Via Genova 3, 10126 Turin, Italy
    Ann Hematol 89:691-9. 2010
    ..The optimal Hct target was not clearly defined, although a value <0.48 looks highly advisable...
  84. doi request reprint Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes
    Dario Ferrero
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy
    Br J Haematol 144:342-9. 2009
    ..44 months; P = 0.036). Our combined therapy, independent of rEPO dosage, achieved in patients with unfavourable response predictors, a rate of anaemia improvement comparable to the best obtained in lower risk patients by high-dose rEPO...
  85. ncbi request reprint Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells
    Francesca Fiore
    Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Eur J Immunol 35:1155-63. 2005
    ..These data indicate that myeloma cells can affect host immunity by priming DC towards a maturation state favoring the generation of T cells with a regulatory rather than an effector phenotype...
  86. ncbi request reprint Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies
    Alessandro Busca
    Divisione Ospedaliera, Azienda Ospedaliera San Giovanni Battista di Torino, Italy
    Med Sci Monit 8:RA221-32. 2002
    ..The present review summarizes the most recent results obtained in this attractive field...
  87. ncbi request reprint Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma
    Massimo Offidani
    Clinica di Ematologia Polo Ospedaliero Universitario, Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, Italy
    Eur J Haematol 78:297-302. 2007
    ..We performed a case-matched study comparing patients with relapsed/refractory MM receiving thalidomide-dexamethasone alone or the combination thalidomide-dexamethasone-liposomal pegylated doxorubicin...
  88. doi request reprint A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, IRCCS Oncology Referral Center of Basilicata, Rionero in Vulture PZ, Italy
    Cancer 113:1588-95. 2008
    ..Few studies published to date have explored the role of BPs in patients with untreated, asymptomatic myeloma (AM). No data are available on the efficacy of zoledronic acid in these patients...
  89. ncbi request reprint Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 89:717-41. 2004
    ....
  90. ncbi request reprint Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system
    Claudia Voena
    Department of Haematology, Laboratory of Molecular Haematology, Istituto H S Raffaele, Milan, Italy
    Br J Haematol 117:642-5. 2002
    ..Quantitative PCR, performed in two patients, showed a tumour depletion of 1 and 2 logs respectively. Although numbers are small, the promising results obtained with small-scale selection were not reproduced in large-scale experiments...
  91. ncbi request reprint Management of multiple myeloma with bortezomib: experts review the data and debate the issues
    Mario Dicato
    Department of Hematology Oncology, Luxembourg Medical Center, Luxembourg, Luxembourg
    Oncology 70:474-82. 2006
    ....
  92. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...
  93. ncbi request reprint Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study
    Antonio Palumbo
    Haematologica 90:858-60. 2005
    ..Multiple regression analysis adjusting for several covariates was used. Improved FACT-An scores in women and men were associated with hemoglobin increase up to sex-specific normal values...
  94. ncbi request reprint Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
    Tommaso Caravita
    Myeloma Unit, Hematology Department, St Eugenio Hospital, Rome, Italy
    Nat Clin Pract Oncol 3:374-87. 2006
    ..This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors...
  95. ncbi request reprint Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells
    Paolo Corradini
    Division of Hematology Bone Marrow Transplantation, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133 Milano, Italy
    J Clin Oncol 22:2172-6. 2004
    ..We performed a pilot study to investigate the role of reduced-intensity conditioning (RIC) followed by allogeneic stem-cell transplantation in relapsed or refractory PTCLs...
  96. pmc Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Blood 111:4039-47. 2008
    ....
  97. ncbi request reprint Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome
    Dario Ferrero
    Haematologica 89:619-20. 2004
    ..5), ineligible for standard chemotherapy. The response rate was 50%, with 27% complete remission. The median survival of the whole group and responders was 7.5 (1-47+) and 16.5 months (3.5-47+), respectively...
  98. ncbi request reprint Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 352:2487-98. 2005
    ..This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies...
  99. doi request reprint Thalidomide and lenalidomide: Mechanism-based potential drug combinations
    Sonia Vallet
    Division of Hematology and Oncology, Cancer Center, Massachusetts General Hospital, Boston, MA, USA
    Leuk Lymphoma 49:1238-45. 2008
    ..Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects...
  100. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  101. pmc MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
    Flavia Pichiorri
    Department of Molecular Virology, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:12885-90. 2008
    ..In summary, we have described a MM miRNA signature, which includes miRNAs that modulate the expression of proteins critical to myeloma pathogenesis...